Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Medicamen Organics Ltd
Quarter-by-quarter operating performance
Financials of Medicamen Organics Ltd
Annual income statement trend
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| Sales + | 25.27 | 38.19 | 39.43 |
| Expenses + | 20.53 | 31.58 | 32.16 |
| Operating Profit | 4.74 | 6.61 | 7.27 |
| OPM % | 18.76% | 17.31% | 18.44% |
| Other Income + | 1.07 | 0.10 | 0.11 |
| Interest | 0.65 | 0.54 | 0.62 |
| Depreciation | 0.72 | 0.74 | 0.78 |
| Profit before tax | 4.44 | 5.43 | 5.98 |
| Tax % | 40.77% | 25.41% | |
| Net Profit + | 2.62 | 4.05 | 4.58 |
| EPS in Rs | 3.05 | 3.46 | 3.91 |
| Dividend Payout % | 0.00% | 0.00% |
Financials of Medicamen Organics Ltd
Capital structure and asset base
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 8.60 | 11.70 | 11.70 |
| Reserves | 6.66 | 18.43 | 20.92 |
| Borrowings + | 12.66 | 12.35 | 15.67 |
| Other Liabilities + | 10.52 | 16.73 | 12.86 |
| Total Liabilities | 38.44 | 59.21 | 61.15 |
| Fixed Assets + | 10.35 | 10.13 | 12.79 |
| CWIP | 0.15 | 2.22 | 0.36 |
| Investments | 0.00 | 0.00 | 0.00 |
| Other Assets + | 27.94 | 46.86 | 48.00 |
| Total Assets | 38.44 | 59.21 | 61.15 |
Financials of Medicamen Organics Ltd
Operating, investing and financing cash movement
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Cash from Operating Activity + | -3.66 | -4.54 |
| Cash from Investing Activity + | -0.34 | -2.35 |
| Cash from Financing Activity + | 4.01 | 10.47 |
| Net Cash Flow | 0.01 | 3.58 |
| Free Cash Flow | -4.01 | -6.99 |
| CFO/OP | -73% | -67% |
Financials of Medicamen Organics Ltd
Working capital efficiency and return ratios
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 241.21 | 247.06 |
| Inventory Days | 244.39 | 228.39 |
| Days Payable | 281.81 | 356.77 |
| Cash Conversion Cycle | 203.80 | 118.69 |
| Working Capital Days | 74.24 | 135.14 |
| ROCE % | 16.88% |
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…